18:19:52 EDT Mon 28 Sep 2020
Enter Symbol
or Name

Login ID:
Isodiol International Inc (2)
Symbol ISOL
Shares Issued 58,180,538
Close 2019-12-03 C$ 0.18
Recent Sedar Documents

ORIGINAL: Isodiol International Inc. Reports Second Quarter 2020 Financial Results

2019-12-03 12:09 ET - News Release

VANCOUVER, BC / ACCESSWIRE / December 3, 2019 / Isodiol International Inc. (CSE:ISOL)(OTCQB:ISOLF)(FSE:LB6B.F) (the "Company" or "Isodiol"), announces that it has filed its consolidated financial statements and MD&A for the three months ended September 30, 2019 and issues shares to settle debt.

Significant FY2020 second quarter results include:

  • The Company has reported revenues of $1.878M for its second quarter. The Company attributes the decrease in revenue primarily to management restructuring and the continued focus on long term, higher margin growth. The Company is in the process of adapting to the volatile market through a focus on rebranding strategies and restructuring our product line to better address changing market needs.
  • The Company has reduced its operational expenditures by $5.1M compared to the three months ended September 30, 2018, and by $300k compared to the most recently completed three months ended June 30, 2019. The reductions in spending have been described in the MD&A for the three months ended June 30, 2019, with highlights below:
Q2 2020 Q1 2020 Change Q2 2019 Change
52,185 49,178 6.11% 1,716,720 -96,96%
848,034 816,238 3.90% 2,560,649 -66.88%
Total operating expenses
3,061,382 3,362,091 -8.94% 12,844,008 -76.16%
Net loss
3,241,110 2,825,092 14.73% 8,616,120 -62,38%
  • Liquidity
    • Positive working capital of $1.8M and includes the following current assets:
      • Cash balance of $303K;
      • Prepaid expenses of $2.5M;
      • Inventory of $1M;
      • Receivables of $5.1M;
      • Investments and loans receivables expected to bring an additional $1.2M of cash before December 2019;
    • Not included in working capital is the long-term receivables from the final BSPG payments of USD$2M expected to be received by September 2020;

Operational highlights:

  • On October 9, 2019 the Company announced the appointment of Andrew Alvis as the Company's President.
  • The Company launched a CBD pet product line, Pawceuticals.
  • The Company also announced that it has entered into a strategic relationship with Vitamin Shoppe, Inc. for the launch of the Company's Iso-Sport products available for their distribution.

The Company also announces that it will be issuing 245,905 shares to settle CAN$83,923 in liabilities at a weighted average price of CAN$0.34 per share.

"The Company's primary objective in Q1 and Q2 of FY2020 was to reduce our operating expenses and move towards profitability through a focus on higher margin sales" said CEO of Isodiol, Marcos Agramont. "We've been successful in pairing down expenses and are now laser focused on re-establishing our name brands and product lines to meet the changing needs of the current and future CBD/Hemp market"

Follow Our Corporate Updates On Facebook at www.facebook.com/IsodiolInternationalInc/, on Twitter @Isodiolintlinc, and on Instagram @isodiol

About Isodiol International Inc.

Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based Consumer Packaged Goods (CPG) and solutions. Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.

Marcos Agramont, CEO & Director



The CSE has not reviewed, approved or disapproved the content of this press release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, proposed arrangement with creditors, products and future the Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

SOURCE: Isodiol International Inc.

View source version on accesswire.com:

© 2020 Canjex Publishing Ltd. All rights reserved.